Information Provided By: 
Fly News Breaks for February 28, 2020
BMRN
Feb 28, 2020 | 06:33 EDT
Citi analyst Mohit Bansal raised the firm's price target on BioMarin to $105 from $95 and keeps a Buy rating on the shares. The analyst cites the company's fiscal 2020 guidance and updated assumptions for Valoctocogene Roxaparvovec and commercial franchise for the target bump. He believes investor interest likely to remain high given expectation for $2B in total revenue and GAAP net income break-even or better for 2020.
News For BMRN From the Last 2 Days
